

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61K 47/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/69469</b> <b>(43) International Publication Date:</b> 23 November 2000 (23.11.00)
<b>(21) International Application Number:</b> PCT/US99/10596 <b>(22) International Filing Date:</b> 13 May 1999 (13.05.99) <b>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application</b> US 08/954,509 (CIP) Filed on 5 November 1997 (05.11.97) <b>(71) Applicant (for all designated States except US):</b> NEXMED HOLDINGS, INC. [US/US]; 350 Corporate Boulevard, Robinsville, NJ 08691 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> YEAGER, James, L. [US/US]; 820 Warwick Road, Deerfield, IL 60015 (US). BUYUKTIMKIN, Nadir [TR/US]; 2313 Willow Creek, Lawrence, KS 66049 (US). BUYUKTIMKIN, Servet [TR/US]; 2313 Willow Creek, Lawrence, KS 66049 (US). <b>(74) Agent:</b> ZIMMERMAN, Roger, P.; McDonnell Boehnen Hulbert & Berghoff, 300 South Wacker Drive, Chicago, IL 60606 (US).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> TOPICAL COMPOSITIONS FOR PROSTAGLANDIN E <sub>1</sub> DELIVERY  <b>(57) Abstract</b>  A composition of a semi-solid consistency is provided for use in the manufacture of a topical medicament for the transdermal application of prostaglandin E <sub>1</sub> . The composition comprises prostaglandin E <sub>1</sub> , a penetration enhancer, a polysaccharide gum, a lipophilic compound, and an acidic buffer system. The penetration enhancer is an alkyl-2-(N,N-disubstituted amino)-alkanoate ester, an(N,N-disubstituted amino)-alkanol alkanoate, or a mixture of these. The lipophilic compound may be an aliphatic C <sub>1</sub> to C <sub>8</sub> alcohol, an aliphatic C <sub>8</sub> to C <sub>30</sub> ester, or a mixture of these. The composition includes a buffer system capable of providing a buffered pH value for said composition in the range of about 3 to about 7.4. The composition is useful for the manufacture of medicaments for the treatment of erectile dysfunction, female sexual dysfunction and peripheral vascular disease.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		


- 1 -

TOPICAL COMPOSITIONS FOR PROSTAGLANDIN E<sub>1</sub> DELIVERYTechnical Field of the Invention

5 This invention relates to pharmaceutical compositions for transdermal or transmucosal administration of prostaglandin drugs to a patient.

Background of the Invention

10 Prostaglandin E<sub>1</sub> is a derivative of prostanoic acid, a 20-carbon atom lipid acid, represented by the formula:



and is commercially available, e.g., from Chinoin  
Pharmaceutical and Chemical Works Ltd. (Budapest, Hungary)  
15 under the designation "Alprostadiol USP" and from The Upjohn  
Company (Kalamazoo, Michigan) under the designation "Prostin  
VR."

Prostaglandin E<sub>1</sub> is a vasodilator useful to maintain  
open blood vessels and therefore, to treat peripheral vascular  
20 disease among other ailments. While the potential benefits  
from transdermal delivery of prostaglandin E<sub>1</sub> have long been  
recognized, prior efforts at developing a topical composition  
for prostaglandin delivery have not been fully successful.

In particular, there is presently no commercial  
25 source for a topical semi-solid formulation that is useful  
without a supporting device such as a patch, adhesive strip,  
and the like. For example, U.S. Patent No. 5,380,760 to Wendel  
et al. is directed to a topical prostaglandin formulation that  
includes a pressure-sensitive, adhesive sheet of

- 2 -

polyisobutylene.

Working alone most drugs, prostaglandin formulations included, do not sufficiently permeate the skin to provide drug concentration levels comparable to those obtained from other drug delivery routes. To overcome this problem, topical drug formulations typically include a skin penetration enhancer. Skin penetration enhancers also may be referred to as absorption enhancers, accelerants, adjuvants, solubilizers, sorption promoters, etc. Whatever the name, such agents serve to improve drug absorption across the skin. Ideal penetration enhancers not only increase drug flux across the skin, but do so without irritating, sensitizing, or damaging skin. Furthermore, ideal penetration enhancers should not affect available dosage forms (e.g. cream or gel), or cosmetic quality of the topical composition.

A wide variety of compounds have been evaluated as to their effectiveness in enhancing the rate of penetration of drugs through the skin. See, for example, *Percutaneous Penetration Enhancers*, Maibach H. I. and Smith H. E. (eds.), CRC Press, Inc., Boca Raton, F.L. (1995), which surveys the use and testing of various skin penetration enhancers, and Büyüktimkin et al., *Chemical Means of Transdermal Drug Permeation Enhancement in Transdermal and Topical Drug Delivery Systems*, Gosh T.K., Pfister W.R., Yum S.I. (Eds.), Interpharm Press Inc., Buffalo Grove, I.L. (1997).

A fully successful formulation for prostaglandin  $E_1$  has not yet been identified. Unfortunately, prostaglandin  $E_1$  is readily transformed by rearrangement and other reactions. This relative instability tends to complicate efforts at formulating composition for transdermal delivery.

The present invention addresses these problems by providing a semi-solid, separation resistant composition for relatively rapid, sustained delivery of prostaglandin  $E_1$ .

#### Summary of the Invention

A pharmaceutical composition suitable for topical application comprises prostaglandin  $E_1$ , a penetration enhancer,

a polysaccharide gum, a lipophilic compound, and an acidic buffer system. The penetration enhancer is an alkyl-2-(N,N-disubstituted amino)-alkanoate ester, an (N,N-disubstituted amino)-alkanol alkanoate, or a mixture of these. The  
5 lipophilic compound may be an aliphatic C<sub>1</sub> to C<sub>8</sub> alcohol, an aliphatic C<sub>8</sub> to C<sub>30</sub> ester, or a mixture of these. The composition includes a buffer system capable of providing a buffered pH value for said composition in the range of about 3 to about 7.4. If desired, stabilizers and emulsifiers may be  
10 included.

Compositions of the present invention can take the form of a semi-solid suitable for topical application. In use as a topical agent, these compositions exhibit relatively high prostaglandin penetration and bioavailability without requiring  
15 a wasteful overloading prostaglandin concentration. The compositions further exhibit reduced skin irritation, sensitivity and damage.

The prostaglandin compositions of the present invention are useful for the treatment of diseases such as  
20 Raynaud's phenomenon, Raynaud's disease, Buerger's disease, livedo reticularis, acrocyanosis atherosclerosis, frostbite, vitiligo, alopecia areata, impending gangrene, and other ischemic disorders. Moreover, the ability of the topical prostaglandin compositions of the present invention to increase  
25 peripheral circulation renders them useful to enhance the rate of healing of wounds, ulcers, infections and proliferative and inflammatory skin lesions including atopic dermatitis, acne and psoriasis; to treat impotency; or to enhance the rate of absorption of pharmaceutically active agents. In addition, the  
30 topical prostaglandin compositions of the present invention may be employed to improve skin color and to promote blush.

The compositions of the present invention can thus be used for the manufacture of pharmaceutical compositions and medicaments that are suitable for the prolonged treatment of  
35 peripheral vascular disease, including the conditions listed above, male erectile dysfunction, female sexual dysfunction and

other disorders treated by prostaglandin  $E_1$ , while avoiding the low bioavailability and rapid chemical decomposition associated with other delivery methods.

Other and further aims, purposes, features, advantages, embodiments and the like will be apparent to those skilled in the art from the present specification and the appended claims.

#### Brief Description of the Drawings

10 In the drawings,

FIGURE 1 is a graph of the cumulative prostaglandin  $E_1$  penetration through shed snake skin of seven prostaglandin  $E_1$  compositions prepared according to the present invention;

15 FIGURE 2 is a comparison graph of the cumulative prostaglandin  $E_1$  penetration through shed snake skin of two prostaglandin  $E_1$  compositions prepared according to the present invention and two comparative compositions.

#### Detailed Description of the Invention

20 The pharmaceutical composition of the present invention comprises prostaglandin  $E_1$ , an alkyl (N,N-disubstituted amino) ester, a polysaccharide gum, a lipophilic compound, and an acid buffer system.


Prostaglandin  $E_1$  is well known to those skilled in the art. Reference may be had to various literature references for its pharmacological activities, side effects, and normal dosage ranges. See for example, *Physician's Desk Reference*, 51st Ed. (1997), *The Merck Index*, 12th Ed., Merck & Co., N.J. (1996), and *Martindale The Extra Pharmacopoeia*, 28th Ed., London, The Pharmaceutical Press (1982). Prostaglandin  $E_1$  as well as other compounds referenced herein are intended to encompass pharmaceutically acceptable derivatives including physiologically compatible salts and ester derivatives thereof.

35 The quantity of prostaglandin  $E_1$  in the pharmaceutical compositions of the present invention is a therapeutically effective amount and necessarily varies

according to the desired dose, the dosage form (e.g.,  
suppository or topical), and the particular form of  
prostaglandin E<sub>1</sub> used. The composition generally contains  
between 0.1 percent to 1 percent prostaglandin E<sub>1</sub>, preferably  
5 from 0.3 percent to 0.5 percent, based on the total weight of  
the composition.

An important component of the present invention is  
the penetration enhancer. The penetration enhancer is an  
alkyl-2-(N,N-disubstituted amino)-alkanoate, an (N,N-  
10 disubstituted amino)-alkanol alkanoate, or a mixture of these.  
For convenient reference, alkyl-2-(N,N-disubstituted amino)-  
alkanoates and (N,N-disubstituted amino)-alkanol alkanoates can  
be grouped together under the label alkyl (N,N-disubstituted  
amino) esters.


15 Alkyl-2-(N,N-disubstituted amino)-alkanoates suitable  
for the present invention can be represented as follows:



wherein n is an integer having a value in the range of about 4  
to about 18; R is a member of the group consisting of hydrogen,  
20 C<sub>1</sub> to C<sub>7</sub> alkyl, benzyl and phenyl; R<sub>1</sub> and R<sub>2</sub> are members of the  
group consisting of hydrogen and C<sub>1</sub> to C<sub>7</sub> alkyl; and R<sub>3</sub> and R<sub>4</sub>  
are members of the group consisting of hydrogen, methyl and  
ethyl.


Preferred alkyl (N,N-disubstituted amino)-alkanoates  
25 are C<sub>4</sub> to C<sub>18</sub> alkyl (N,N-disubstituted amino)-acetates and C<sub>4</sub> to  
C<sub>18</sub> alkyl (N,N-disubstituted amino)-propionates. Exemplary  
specific alkyl-2-(N,N-disubstituted amino)-alkanoates include

dodecyl 2-(N,N dimethylamino)-propionate (DDAIP);



and dodecyl 2-(N,N-dimethylamino)-acetate (DDAA);

5




Alkyl-2-(N,N-disubstituted amino)-alkanoates are known. For example, dodecyl 2-(N,N-dimethylamino)-propionate (DDAIP) is available from Steroids, Ltd. (Chicago, IL). In addition, alkyl-2-(N,N-disubstituted amino)-alkanoates can be synthesized from more readily available compounds as described in U.S. Patent No. 4,980,378 to Wong et al., which is incorporated herein by reference to the extent that it is not inconsistent. As described therein, alkyl-2-(N,N-disubstituted amino)-alkanoates are readily prepared via a two-step synthesis. In the first step, long chain alkyl chloroacetates are prepared by reaction of the corresponding long chain alkanols with chloromethyl chloroformate or the like in the presence of an appropriate base such as triethylamine, typically in a suitable solvent such as chloroform. The reaction can




- 7 -

be depicted as follows:



- 5 wherein R, R<sub>3</sub>, R<sub>4</sub> and n are defined as above. The reaction temperature may be selected from about 10EC. to about 200EC. or reflux, with room temperature being preferred. The use of a solvent is optional. If a solvent is used, a wide variety of organic solvents may be selected.
- 10 Choice of a base is likewise not critical. Preferred bases include tertiary amines such as triethylamine, pyridine and the like. Reaction time generally extends from about one hour to three days.


- 15 In the second step, the long chain alkyl chloroacetate is condensed with an appropriate amine according to the scheme:



wherein n, R, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> are defined as before. Excess

amine reactant is typically used as the base and the reaction is conveniently conducted in a suitable solvent such as ether. This second step is preferably run at room temperature, although temperature may vary. Reaction time usually varies from about one hour to several days. Conventional purification techniques can be applied to ready the resulting ester for use in a pharmaceutical compound.


Suitable (N,N-disubstituted amino)-alkanol alkanoates can be represented by the formula:



10


wherein n is an integer having a value in the range of about 5 to about 18; y is an integer having a value in the range of 0 to about 5; and R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, and R<sub>7</sub> are members of the group consisting of hydrogen, C<sub>1</sub> to C<sub>8</sub> alkyl, and C<sub>1</sub> to C<sub>8</sub> aryl; and R<sub>8</sub> is a member of the group consisting of hydrogen, hydroxyl, C<sub>1</sub> to C<sub>8</sub> alkyl, and C<sub>1</sub> to C<sub>8</sub> aryl.

Preferred (N,N-disubstituted amino)-alkanol alkanoates are C<sub>5</sub> to C<sub>18</sub> carboxylic acid esters. Exemplary specific (N,N-disubstituted amino)-alkanol alkanoates include 1-(N,N-dimethylamino)-2-propanol dodecanoate (DAIPD);




1-(N,N-dimethylamino)-2-propanol myristate (DAIPM);

- 9 -



1- (N,N-dimethylamino)-2-propanol oleate (DAIPO);



5

The (N,N-disubstituted amino)-alkanol alkanoates are readily prepared by reacting the corresponding aminoalkinol with lauroyl chloride in the presence of triethylamine. A solvent such as chloroform is optional but preferred. For  
 10 example, 1-(N,N-dimethylamino)-2-propanol can be reacted with lauroyl chloride in chloroform and in the presence of triethylamine to form 1-(N,N-dimethylamino)-2-propanol dodecanoate (DAIPD).

15 Among the suitable penetration enhancers for the present invention DDAIP is generally preferred.

The penetration enhancer is present in an amount sufficient to enhance the penetration of the prostaglandin  $E_1$ . The specific amount varies necessarily according to the desired release rate and the specific form of prostaglandin  $E_1$  used.  
 20 Generally, this amount ranges from about 0.5 percent to about 10 percent, based on the total weight of the composition. Preferably, the penetration enhancer is about 5 weight percent of the composition.

Polysaccharide gums are also an important ingredient  
 25 to the present composition. Suitable representative gums are those in the galactomannan gum category. A galactomannan gum

- 10 -

is a carbohydrate polymer containing D-galactose and D-mannose units, or other derivatives of such a polymer. There is a relatively large number of galactomannans, which vary in composition depending on their origin. The galactomannan gum is characterized by a linear structure of  $\beta$ -D-mannopyranosyl units linked (1 $\rightarrow$ 4). Single membered  $\alpha$ -D-manopyranosyl units, linked (1 $\rightarrow$ 6) with the main chain, are present as side branches. Galactomannan gums include guar gum, which is the pulverized endosperm of the seed of either of two leguminous plants (*Cyamopsis tetragonalobus* and *psoraloids*) and locust bean gum, which is found in the endosperm of the seeds of the carobtree (*ceratonia siliqua*). Locust bean gum is preferred for the present invention.

Other suitable representative gums include agar gum, carrageenan gum, ghatti gum, karaya gum, rhamsan gum and xanthan gum. The composition of the present invention may contain a mixture of various gums, or mixture of gums and acidic polymers.

Gums, and galactomannan gums in particular, are well-known materials. See for instance, *Industrial Gums: Polysaccharides & Their Derivatives*, Whistler R. L. and BeMiller J.N. (eds.), 3rd Ed. Academic Press (1992) and Davidson R. L., *Handbook of Water-Soluble Gums & Resins*, McGraw-Hill, Inc., N.Y. (1980). Most gums are commercially available in various forms, commonly a powder, and ready for use in foods and topical compositions. For example, locust bean gum in powdered form is available from Tic Gums Inc. (Belcam, MD).

The polysaccharide gums are represent in the range from about 0.5 percent to about 5 percent, based on the total weight of the composition, with the preferred range being from 0.5 percent to 2 percent. Illustrative compositions are given in the examples, below.

An optional alternative to the polysaccharide gum is a polyacrylic acid polymer. A common variety of polyacrylic acid polymer is known generically as "carbomer." Carbomer is

- 11 -

polyacrylic acid polymers lightly cross-linked with polyalkenyl polyether. It is commercially available from the B. F. Goodrich Company (Akron, Ohio) under the designation "CARBOPOL™." A particularly preferred variety of carbomer is that designated as "CARBOPOL 940."

Other polyacrylic acid polymers suitable for use in practicing this invention are those commercially available under the designations "Pemulen™" (B. F. Goodrich Company) and "POLYCARBOPHIL™" (A.H. Robbins, Richmond, VA). The Pemulen™ polymers are copolymers of C<sub>10</sub> to C<sub>30</sub> alkyl acrylates and one or more monomers of acrylic acid, methacrylic acid or one of their simple esters crosslinked with an allyl ether of sucrose or an allyl ether of pentaerythritol. The POLYCARBOPHIL™ enhancer is a polyacrylic acid cross-linked with divinyl glycol.

Where polyacrylic acid polymers are present, they represent about 0.5 percent to about 5 percent of the composition, based on its total weight.

Another important component of the present invention is a lipophilic compound. The term lipophilic compound as used herein refers to an agent that is both lipophilic and hydrophilic. The C<sub>1</sub> to C<sub>8</sub> aliphatic alcohols, the C<sub>2</sub> to C<sub>30</sub> aliphatic esters, and their mixtures can serve as lipophilic compound. Illustrative suitable alcohols are ethanol, n-propanol and isopropanol, while suitable esters are ethyl acetate, butyl acetate, ethyl laurate, methyl propionate and isopropyl myristate. As used herein, the term "aliphatic alcohol" includes polyols such as glycerol, propylene glycol and polyethylene glycols. A mixture of alcohol and ester is preferred, and in particular, a mixture of ethanol and ethyl laurate myristate is most preferred.

The concentration of lipophilic compound required necessarily varies according to other factors such as the desired semi-solid consistency and the desired skin penetration promoting effects. The preferred topical composition contains lipophilic compound in the range of 7 percent to 40 percent by weight based on the total weight of the composition. Where a

5 mixture of aliphatic alcohol and aliphatic ester are employed, the preferred amount of alcohol is in the range of 5 percent to 15 percent, while that of aliphatic ester is in the range from 2 percent to 15 percent (again based on the total weight of the composition).

10 An optional, but preferred, component of the present invention is an emulsifier. Although not a critical factor, a suitable emulsifier generally will exhibit a hydrophilic-lipophilic balance number greater than 10. Sucrose esters, and specifically sucrose stearate, can serve as emulsifiers for the topical composition of the present invention. Sucrose stearate is a well known emulsifier available from various commercial sources. When an emulsifier is used, sucrose stearate present up to about 2 percent, based on the total weight of the composition, is preferred. The preferred amount of sucrose stearate emulsifier can also be expressed as a weight ratio of emulsifier to polysaccharide gum. A ratio of 1 to 6 emulsifier to gum is preferred, and a ratio of 1 to 4 is most preferred to generate the desired semi-solid consistency and separation resistance.

20 The present invention includes an acid buffer system. Acid buffer systems serve to maintain or buffer the pH of compositions within a desired range. The term "buffer system" or "buffer" as used herein has reference to a solute agent or agents which, when in a water solution, stabilize such solution against a major change in pH (or hydrogen ion concentration or activity) when acids or bases are added thereto. Solute agent or agents which are thus responsible for a resistance to change in pH from a starting buffered pH value in the range indicated above are well known. While there are countless suitable buffers, potassium phosphate monohydrate has proven effective for compositions of the present invention.

30 The final pH value of the pharmaceutical composition of the present invention may vary within the physiologically compatible range. Necessarily, the final pH value is not irritating to human skin. Without violating this constraint,

- 13 -

the pH may be selected to improve prostaglandin E<sub>1</sub> stability and to adjust consistency when required. With these factors accounted for, the preferred pH value is about 3.0 to 7.4. The most preferred pH range is from about 3.5 to about 6.0.

5           The remaining component of the composition is water, which is necessarily purified. The composition contains water in the range of about 50 to about 90 percent, based on the total weight of the composition. The specific amount of water present is not critical, however, being adjustable to obtain  
10 the desired consistency and/or concentration of the other components.

          Additionally, known transdermal penetration enhancers can also be added, if desired. Illustrative are dimethyl sulfoxide (DMSO), dimethyl acetamide (DMA), 2-pyrrolidone, N,N-  
15 diethyl-m-toluamide (DEET), 1-dodecylazacycloheptane-2-one (Azone™, a registered trademark of Nelson Research), N,N-dimethylformamide, N-methyl-2-pyrrolidone, calcium thioglycolate, oxazolidinone, dioxolane derivatives, laurocapram derivatives, and macrocyclic enhancers such as  
20 macrocyclic ketones.

          Prostaglandin E<sub>1</sub> stabilizers, coloring agents, rheological agents, and preservatives can be added to the extent that they do not overly limit prostaglandin E<sub>1</sub> skin penetration or prevent the desired semi-solid consistency.

25           Contemplated dosage forms of the semi-solid pharmaceutical composition of the present invention are creams, gels, and the like, also including but not limited to compositions suitable for use with transdermal patches and like devices.

30           The ingredients listed above may be combined in any order and manner that produces a stable composition comprising a prostaglandin E<sub>1</sub> evenly dispersed throughout a semi-solid formulation. One available approach to preparing such compositions involves evenly dispersing the polysaccharide gum  
35 (or polyacrylic acid) in a premixed water/buffer solution and then thoroughly homogenizing (i.e. mixing) the resulting

5 mixture, which will be labelled "Part A." When present, the emulsifier is added to the water/buffer solution before dispersing the polysaccharide gum. Any suitable method of adjusting the pH value of Part A to the desired level may be used, for example, by adding concentrated phosphoric acid or sodium hydroxide.

10 Separately, the prostaglandin  $E_1$  is dissolved with agitation in the lipophilic compound, which itself may be a mixture of alcohols, esters, or alcohol with ester. Next, the penetration enhancer is added. Alternatively, when the lipophilic compound includes both an alcohol and an ester, the prostaglandin  $E_1$  can be dissolved in the alcohol before adding the penetration enhancer followed by the ester. In either case, the resulting mixture will be labelled "Part B." The final step involves slow addition (e.g. dropwise) of Part B into Part A under constant mixing.

20 The resulting topical composition, when compared to existing commercially available compositions, exhibits the advantageous properties described above, including improved prostaglandin  $E_1$  permeation and bioavailability without drug overloading, reduced damage and related inflammation to skin or mucous membranes, and increased flexibility in design of dosage forms. These compositions can be used for the manufacture of pharmaceutical compositions that are suitable for the prolonged treatment of peripheral vascular disease, male impotency, male erectile dysfunction, female sexual dysfunction and other disorders treated by prostaglandin  $E_1$ , while avoiding the low bioavailability and rapid chemical decomposition associated with other delivery methods. These compositions can be used for the manufacture of pharmaceutical compositions that are suitable for the enhancement of the sexual response of normal (i.e., orgasmic) human females. Application of prostaglandin  $E_1$  in a topical composition of the present invention to the skin or mucous membrane of a patient allows a predetermined amount of prostaglandin  $E_1$  to be administered continuously to the patient and avoids undesirable effects present with a single or



- 15 -

multiple administrations of larger dosages by injection. By maintaining a sustained dosage rate, the prostaglandin E<sub>1</sub> level in the patient's target tissue can be better maintained within the optimal therapeutic range.

5           The practice of the present invention is demonstrated in the following examples. These examples are meant to illustrate the invention rather than to limit its scope. Variations in the treating compositions which do not adversely affect the effectiveness of prostaglandin E<sub>1</sub> will be evident to  
10 one skilled in the art, and are within the scope of this invention. For example, additional ingredients such as coloring agents, anti-microbial preservatives, emulsifiers, perfumes, prostaglandin E<sub>1</sub> stabilizers, and the like may be included in the compositions as long as the resulting  
15 composition retains desirable properties, as described above. Unless otherwise indicated, each composition is prepared by conventionally admixing the respective indicated components together.

**EXAMPLE 1: Topical Prostaglandin E<sub>1</sub> Composition A**

20           Composition A was prepared as follows. Part A was formed by dissolving 0.4 parts prostaglandin E<sub>1</sub> (Alprostadil USP) in 5 parts ethyl alcohol. Next, 5 parts dodecyl 2-(N,N-dimethylamino)-propionate were mixed into the alcohol-prostaglandin E<sub>1</sub> solution, followed by 5 parts ethyl laurate.

25           Part B was prepared starting from a pH 5.5 water/buffer solution. The water/buffer solution was prepared by adding sufficient potassium phosphate monohydrated to purified water to create a 0.1 M solution. The pH of the water/buffer solution was adjusted to 5.5 with a strong base  
30 solution (1 N sodium hydroxide) and a strong acid (1 N phosphoric acid). The buffer solution represented about 80 parts of the total composition.

          To the buffer solution, was added 0.5 parts ethyl laurate. Next, the locust bean gum (in powder form) was  
35 dispersed in the buffer solution and homogenized using a homogenizer. TABLE 1, below, contains a list of ingredients.

The resulting composition was a spreadable, semi-solid suitable for application to the skin without the need for supporting devices such as patches and adhesive strips. The composition was both homogenous in appearance and resistant to separation.

Composition A was evaluated for skin penetration using shed snake skin as a model barrier. Shed snake skin was obtained from the Animal Care Unit of the University of Kansas. With head and tail sections removed, the skin was randomly divided into test sections and then hydrated by soaking.

The samples were then evaluated using Franz-type Diffusion Cells (surface area 1.8 cm<sup>2</sup>). Specifically, skin pieces were mounted on top of a receptor cell of a vertical diffusion cell assembly in which a small magnetic bar was inserted and filled with an isotonic buffer. A seal was placed on top of the skin section followed by a donor cell. The two cells were clamped together. Known amounts of the formulations were applied on the bottom of a small capped vial (weight .5 grams) which fits exactly to the donor cell to ensure uniform distribution. The vials were placed on the skin in the donor cell. To reduce the evaporation of the ingredients, the donor cell and vial were gently taped together with a water-resistant adhesive band. The cells were transferred to a stirred water bath (32°C.). Samples were withdrawn from the cells each hour for four hours and analyzed for the concentration of prostaglandin E<sub>1</sub>, with changes in concentration indicating the amount penetrating. Tests with multiple skin samples yielded data that were averaged.

For a discussion of the use of shed snake skin in the evaluation of drug penetration, see U.S. Patent No. 4,771,004 to Higuchi, which is incorporated here by reference to the extent that it is not inconsistent.

The prostaglandin E<sub>1</sub> penetrated quickly at a relatively sustained rate for four hours. The results of the penetration study are presented in TABLE 2, below, and in FIGURE 1.

- 17 -

**EXAMPLE 2: Topical Prostaglandin E<sub>1</sub> Composition B**

Composition B was prepared using the ingredients listed in TABLE 1, below. Composition B contained more prostaglandin E<sub>1</sub> than Composition A. Despite this increased  
5 drug loading, Composition B exhibited a similar semi-solid consistency and homogenous appearance. The penetration of prostaglandin E<sub>1</sub> was measured according to the technique described in Example 1. Composition B provided a relatively fast, sustained delivery of prostaglandin E<sub>1</sub>. The results are  
10 presented in TABLE 2, below, and in FIGURE 1.

**EXAMPLE 3: Topical Prostaglandin E<sub>1</sub> Composition C**

Composition C was prepared using the ingredients listed in TABLE 1, below. Composition B contained more prostaglandin E<sub>1</sub> than either Composition A or B. The increased  
15 drug loading had little or no effect on the consistency or appearance, which substantially matched that of Compositions A and B. The penetration of prostaglandin E<sub>1</sub> was again measured according to the technique described in Example 1. According to this test, Composition C also provided a relatively fast,  
20 sustained delivery of prostaglandin E<sub>1</sub>. The results are presented in TABLE 2, below, and in FIGURE 1.

**EXAMPLE 4: Topical Prostaglandin E<sub>1</sub> Composition D**

Composition D was prepared using the ingredients listed in TABLE 1, below. The level of prostaglandin E<sub>1</sub> was  
25 again increased without substantially affecting the favorable consistency and separation resistance. The penetration of prostaglandin E<sub>1</sub> was again measured according to the technique described in Example 1. The results are presented in TABLE 2, below, and in FIGURE 1.

30

**EXAMPLE 5: Topical Prostaglandin E<sub>1</sub> Composition E**

Composition E was prepared using the ingredients listed in TABLE 1, below. To assess the repeatability of  
35 compositions according to the present invention, the recipe of Composition D was again applied for Composition E.

Repeatability was substantially confirmed by Composition E's favorable, semi-solid consistency and separation resistance. The penetration of prostaglandin E<sub>1</sub> was again measured according to the technique described in Example 1. The prostaglandin E<sub>1</sub> delivery from Composition E was again relatively fast and sustained. The results are presented in TABLE 2, below, and in FIGURE 1.

**EXAMPLE 6: Topical Prostaglandin E<sub>1</sub> Composition F**

The level of prostaglandin E<sub>1</sub> was again increased for Composition F. The specific ingredients are listed in TABLE 1. The favorable consistency and separation resistance was undiminished. The results of a penetration analysis are presented in TABLE 2, below, and in FIGURE 1.

**EXAMPLE 7: Topical Prostaglandin E<sub>1</sub> Composition G**

Composition G was prepared using the ingredients listed in TABLE 1. For Composition G, the recipe of Composition F was repeated except that the ester component (ester laurate) was omitted and the level of ethanol was increased a corresponding amount. The resulting composition was also a spreadable, semi-solid having a homogenous appearance and resistance to separation. The results of a penetration analysis are presented in TABLE 2, below, and in FIGURE 1. While still favorable, these results reflect the relative benefit to compositions of the present invention from a lipophilic compound that includes both an ester component and an alcohol component.

**TABLE 1: Topical Prostaglandin E<sub>1</sub> Compositions**

Ingredient (wt%)		A	B	C	D	E	F	G
Part A:	prehydrated locust bean gum	3	3	3	3	3	3	3
	water/buffer (pH 5.5)	81	81	81	81	81	81	81
	sucrose stearate	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Part B:	prostaglandin E <sub>1</sub>	0.1	0.2	0.3	0.4	0.4	0.5	0.4
	DDAIP	5	5	5	5	5	5	5
	ethanol	5	5	5	5	5	5	10
	ethyl laurate	5	5	5	5	5	5	-

- 19 -

**EXAMPLE 8: Comparison of Penetration Profiles**

TABLE 2 shows the cumulative amount of prostaglandin E<sub>1</sub> penetrating each hour for 4 hours for each example composition according to the present invention. These data demonstrate the ability of the present invention to delivery prostaglandin E<sub>1</sub> drugs transdermally.

FIGURE 1 is graph generated from the data presented in TABLE 1. Significantly, and well represented in graphical form, compositions according to the present invention deliver effective skin penetration relatively fast and at a sustained rate. As expected, cumulative penetration increases with increased prostaglandin E<sub>1</sub> loading of the source composition.

**TABLE 2: Cumulative Prostaglandin E<sub>1</sub> Penetration ( $\mu\text{g}/\text{cm}^2$ )**

Hour	A	B	C	D	E	F	G
1	1.96	3.37	5.47	7.20	7.09	10.38	3.03
2	5.49	9.72	18.06	21.26	16.6	25.03	8.17
3	11.25	18.18	30.34	35.53	28.24	42.18	12.93
4	13.98	23.48	38.49	47.98	41.1	52.13	18.71

To further asses the effectiveness of compositions according the present invention, comparative example compositions were prepared. A first comparative example (Comparative Example 1) was prepared with the same recipe as Compositions D and E except that the DDAIP penetration enhancer was omitted. For A second comparative example (Comparative Example 2), the DDAIP was again omitted, but the level of ethanol was increased a corresponding amount. The specific ingredients used are listed in TABLE 3, below.

- 20 -

TABLE 3: Comparative Examples

	Ingredient (wt%)	Comparative Composition 1	Comparative Composition 2
Part A:	prehydrated locust bean gum	3	3
	water/buffer (pH 5.5)	86	81
	sucrose stearate	0.5	0.5
Part B:	prostaglandin E <sub>1</sub>	0.4	0.4
	ethanol	5	10
	ethyl laurate	5	5

The penetration of prostaglandin E<sub>1</sub> from was evaluated according to the technique described in Example 1. The results are presented in TABLE 4, below.

TABLE 4: Comparative Examples  
Cumulative Prostaglandin E<sub>1</sub> Penetration (μg/cm<sup>2</sup>)

Hour	Comparative Composition 1	Comparative Composition 2
1	2.64	1.55
2	4.46	3.69
3	6.59	6.63
4	9.67	11.05

10

The data of TABLE 4 are compared graphically to the example compositions having the same prostaglandin E<sub>1</sub> loading, Compositions D and E. The penetration data demonstrate that compositions according to the present invention benefit greatly from the presence of the DDAIP penetration enhancer.

The foregoing specification is intended as illustrative and is not to be taken as limiting. Still other variations within the spirit and the scope of the invention are possible and will readily present themselves to those skilled in the art.


20

- 21 -

We Claim:

1. A topical composition which comprises:  
 prostaglandin E<sub>1</sub>;  
 a skin penetration enhancer which is a member of the  
 5 group consisting of an alkyl-2-(N,N-disubstituted amino)-  
 alkananoate, an (N,N-disubstituted)-alkanol alkananoate, and a  
 mixture thereof;  
 a polysaccharide gum or a polyacrylic acid polymer;  
 a lipophilic compound which is a member of the group  
 10 consisting of an aliphatic C<sub>1</sub> to C<sub>8</sub> alcohol, an aliphatic C<sub>8</sub> to  
 C<sub>30</sub> ester, and a mixture thereof; and  
 an acidic buffer system.
2. The topical composition in accordance with claim  
 1 wherein said penetration enhancer is a alkyl-2-  
 15 (N,N-disubstituted amino)-alkanoate represented by the formula:
 
$$\begin{array}{c}
 \text{R}_3 \qquad \qquad \text{O} \qquad \text{H} \qquad \text{R}_1 \\
 | \qquad \qquad \parallel \qquad | \qquad / \\
 \text{H}_3\text{C}-(\text{CH}_2)_n-\text{C}-\text{O}-\text{C}-\text{C}-\text{N} \\
 | \qquad \qquad \qquad \qquad | \qquad | \qquad \backslash \\
 \text{R}_4 \qquad \qquad \qquad \qquad \text{R} \qquad \text{R}_2
 \end{array}$$
- wherein n is an integer having a value in the range of about 4  
 to about 18; R is a member of the group consisting of hydrogen,  
 C<sub>1</sub> to C<sub>7</sub> alkyl, benzyl and phenyl; R<sub>1</sub> and R<sub>2</sub> are members of the  
 20 group consisting of hydrogen and C<sub>1</sub> to C<sub>7</sub> alkyl; and R<sub>3</sub> and R<sub>4</sub>  
 are members of the group consisting of hydrogen, methyl and  
 ethyl.
3. The topical composition in accordance with claim  
 1 wherein said penetration enhancer is a C<sub>4</sub> to C<sub>18</sub> alkyl  
 25 (N,N-disubstituted amino)-acetate.
4. The topical composition in accordance with claim  
 1 wherein said penetration enhancer is a dodecyl  
 (N,N-dimethylamino)-acetate.
5. The topical composition in accordance with claim  
 1 wherein said penetration enhancer is a dodecyl  
 30 2-(N,N-dimethylamino)-propionate.

6. The topical composition in accordance with claim 1 wherein said penetration enhancer is an (N,N-disubstituted amino)-alkanol alkanoate represented by the formula:



5 wherein n is an integer having a value in the range of about 5 to about 18; y is an integer having a value in the range of 0 to about 5; and R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, and R<sub>7</sub> are members of the group consisting of hydrogen, C<sub>1</sub> to C<sub>8</sub> alkyl, and C<sub>1</sub> to C<sub>8</sub> aryl; and R<sub>8</sub> is a member of the group consisting of hydrogen,  
10 hydroxyl, C<sub>1</sub> to C<sub>8</sub> alkyl, and C<sub>1</sub> to C<sub>8</sub> aryl.

7. The topical composition in accordance with claim 1 wherein said penetration enhancer is a C<sub>5</sub> to C<sub>18</sub> carboxylic acid ester.

15 8. The topical composition in accordance with claim 1 wherein said penetration enhancer is a 1-(N,N-dimethylamino)-2-propanol dodecanoate.

9. The topical composition in accordance with claim 1 wherein said penetration enhancer is a  
20 1-(N,N-dimethylamino)-2-propanol myristate.

10. The topical composition in accordance with claim 1 wherein said penetration enhancer is a 1-(N,N-dimethylamino)-2-propanol oleate.

25 11. The topical composition in accordance with claim 1 wherein said polysaccharide gum is a galactomannan gum.

12. The topical composition in accordance with claim 11 wherein said galactomannan gum is a locust bean gum.



- 23 -

13. The topical composition in accordance with claim 11 wherein said galactomannan gum is a guar gum.

14. The topical composition in accordance with claim 1 wherein said lipophilic compound is ethanol.

5 15. The topical composition in accordance with claim 1 wherein said lipophilic compound is a polyol aliphatic alcohol.

16. The topical composition in accordance with claim 1 wherein said lipophilic compound is isopropyl myristate.

10 17. The topical composition in accordance with claim 1 wherein said lipophilic compound is ethyl laurate.

18. The topical composition in accordance with claim 1 wherein said lipophilic compound is a mixture of ethanol and isopropyl myristate.

15 19. The topical composition in accordance with claim 1 wherein said lipophilic compound is a mixture of ethanol and ethyl laurate.

20 20. The topical composition in accordance with claim 1 wherein said acidic buffer system is capable of providing a buffered pH value for said composition in the range of about 3 to about 7.4.

21. The topical composition in accordance with claim 1 wherein said penetration enhancer is a dodecyl 25 2-(N,N-dimethylamino)-propionate, said polysaccharide gum is a locust bean gum, and said lipophilic compound is a mixture of ethanol and ethyl laurate.

22. A topical composition in accordance with claim 1, which contains 0.5 to 5 weight percent locust bean gum, 0.5 30 to 25 weight percent dodecyl 2-(N,N-dimethylamino)-propionate, 0.5 to 80 weight percent ethanol, and 0.5 to 80 weight percent isopropyl myristate, based on the total weight of the composition.

23. A topical composition in accordance with claim 35 1, which contains 0.5 to 5 weight percent locust bean gum, 0.5 to 5 weight percent dodecyl 2-(N,N-dimethylamino)-propionate,

0.5 to 25 weight percent ethanol, and 0.5 to 25 weight percent ethyl laurate, based on the total weight of the composition for the manufacture of a topical pharmaceutical dosage form.

24. A topical composition in accordance with claim 1, which further contains an emulsifier.

25. A topical composition in accordance with claim 24 wherein said emulsifier is an sucrose ester.

26. A topical composition in accordance with claim 24 wherein said emulsifier is sucrose stearate.

27. A topical prostaglandin composition which comprises:

prostaglandin E<sub>1</sub>;

a skin penetration enhancer which is a member of the group consisting of an alkyl-2-(N,N-disubstituted amino)-alkanoate, an (N,N-disubstituted)-alkanol alkanoate, and a mixture thereof;

a polyacrylic acid polymer;

a lipophilic compound which is a member of the group consisting of an aliphatic C<sub>1</sub> to C<sub>8</sub> alcohol, an aliphatic C<sub>8</sub> to C<sub>30</sub> ester, and a mixture thereof; and

an acidic buffer system for the manufacture of a topical pharmaceutical dosage form.

28. A topical composition in accordance with claim 27 wherein said polyacrylic acid polymer is a carbomer.

29. The use of a topical composition in accordance with any one of claims 1 to 28 for the preparation of a pharmaceutical composition for transdermal or transmucosal administration.

30. The use of the composition according to claim 29 for the treatment of female sexual dysfunction in a human female.

31. The use of the composition according to claim 29 for the treatment of peripheral vascular disease.

32. The use of the composition according to claim 29 for the treatment of male erectile dysfunction.

33. The use of the composition according to claim 29

SUBSTITUTE SHEET (RULE 26)

- 25 -

for the enhancement of sexual responsiveness in a human female.

1/2




FIG. 1

2/2




FIG. 2

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 99/10596

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61K47/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 99 22714 A (NEXMED HOLDINGS) 14 May 1999 (1999-05-14) claims 1-28 -----	1-33

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

26 January 2000

Date of mailing of the international search report

02/02/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Ventura Amat, A

Form PCT/ISA/210 (second sheet) (July 1992)

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 10596

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 29-33 are directed to a method of treatment of  
of the human/animal body, the search has been carried out and  
based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/10596

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9922714 A	14-05-1999	NONE	

Form PCT/ISA/210 (patent family annex) (July 1992)



1/2




FIG. 1

2/2




FIG. 2